Copyright Reports & Markets. All rights reserved.

Europe Pulmonary Drugs Market Report 2018

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Definition and Specification
    • 1.2 Report Overview
      • 1.2.1 Manufacturers Overview
      • 1.2.2 Regions Overview
      • 1.2.3 Type Overview
      • 1.2.4 Application Overview
    • 1.3 Industrial Chain
      • 1.3.1 Pulmonary Drugs Overall Industrial Chain
      • 1.3.2 Upstream
      • 1.3.3 Downstream
    • 1.4 Industry Situation
      • 1.4.1 Industrial Policy
      • 1.4.2 Product Preference
      • 1.4.3 Economic/Political Environment
    • 1.5 SWOT Analysis

    2 Market Analysis by Types

    • 2.1 Overall Market Performance(Volume)
      • 2.1.1 Inhaled Corticosteroids (ICS) Market Performance (Volume)
      • 2.1.2 Long-Acting Beta2-Agonists (LABA) Market Performance (Volume)
      • 2.1.3 Antihistamine Market Performance (Volume)
      • 2.1.4 Vasodilators Market Performance (Volume)
      • 2.1.5 Short-Acting Beta2-Agonists (SABA) Market Performance (Volume)
    • 2.2 Overall Market Performance(Value)
      • 2.1.1 Inhaled Corticosteroids (ICS) Market Performance (Value)
      • 2.1.2 Long-Acting Beta2-Agonists (LABA) Market Performance (Value)
      • 2.1.3 Antihistamine Market Performance (Value)
      • 2.1.4 Vasodilators Market Performance (Value)
      • 2.1.5 Short-Acting Beta2-Agonists (SABA) Market Performance (Value)

    3 Product Application Market

    • 3.1 Overall Market Performance (Volume)
      • 3.1.1 Asthma & COPD Market Performance (Volume)
      • 3.1.2 Allergic Rhinitis Market Performance (Volume)
      • 3.1.3 Pulmonary Arterial Hypertension Market Performance (Volume)
      • 3.1.4 Cystic Fibrosis Market Performance (Volume)

    4 Manufacturers Profiles/Analysis

    • 4.1 AstraZeneca plc
      • 4.1.1 AstraZeneca plc Profiles
      • 4.1.2 AstraZeneca plc Product Information
      • 4.1.3 AstraZeneca plc Pulmonary Drugs Business Performance
      • 4.1.4 AstraZeneca plc Pulmonary Drugs Business Development and Market Status
    • 4.2 Bayer AG?
      • 4.2.1 Bayer AG? Profiles
      • 4.2.2 Bayer AG? Product Information
      • 4.2.3 Bayer AG? Pulmonary Drugs Business Performance
      • 4.2.4 Bayer AG? Pulmonary Drugs Business Development and Market Status
    • 4.3 Teva Pharmaceutical Industries Ltd.?
      • 4.3.1 Teva Pharmaceutical Industries Ltd.? Profiles
      • 4.3.2 Teva Pharmaceutical Industries Ltd.? Product Information
      • 4.3.3 Teva Pharmaceutical Industries Ltd.? Pulmonary Drugs Business Performance
      • 4.3.4 Teva Pharmaceutical Industries Ltd.? Pulmonary Drugs Business Development and Market Status
    • 4.4 Actelion Pharmaceuticals, Inc.
      • 4.4.1 Actelion Pharmaceuticals, Inc. Profiles
      • 4.4.2 Actelion Pharmaceuticals, Inc. Product Information
      • 4.4.3 Actelion Pharmaceuticals, Inc. Pulmonary Drugs Business Performance
      • 4.4.4 Actelion Pharmaceuticals, Inc. Pulmonary Drugs Business Development and Market Status
    • 4.5 Boehringer Ingelheim GmbH
      • 4.5.1 Boehringer Ingelheim GmbH Profiles
      • 4.5.2 Boehringer Ingelheim GmbH Product Information
      • 4.5.3 Boehringer Ingelheim GmbH Pulmonary Drugs Business Performance
      • 4.5.4 Boehringer Ingelheim GmbH Pulmonary Drugs Business Development and Market Status
    • 4.6 F. Hoffmann-La Roche Ltd.
      • 4.6.1 F. Hoffmann-La Roche Ltd. Profiles
      • 4.6.2 F. Hoffmann-La Roche Ltd. Product Information
      • 4.6.3 F. Hoffmann-La Roche Ltd. Pulmonary Drugs Business Performance
      • 4.6.4 F. Hoffmann-La Roche Ltd. Pulmonary Drugs Business Development and Market Status
    • 4.7 Merck & Co., Inc.
      • 4.7.1 Merck & Co., Inc. Profiles
      • 4.7.2 Merck & Co., Inc. Product Information
      • 4.7.3 Merck & Co., Inc. Pulmonary Drugs Business Performance
      • 4.7.4 Merck & Co., Inc. Pulmonary Drugs Business Development and Market Status
    • 4.8 Novartis AG
      • 4.8.1 Novartis AG Profiles
      • 4.8.2 Novartis AG Product Information
      • 4.8.3 Novartis AG Pulmonary Drugs Business Performance
      • 4.8.4 Novartis AG Pulmonary Drugs Business Development and Market Status
    • 4.9 GlaxoSmithKline plc
      • 4.9.1 GlaxoSmithKline plc Profiles
      • 4.9.2 GlaxoSmithKline plc Product Information
      • 4.9.3 GlaxoSmithKline plc Pulmonary Drugs Business Performance
      • 4.9.4 GlaxoSmithKline plc Pulmonary Drugs Business Development and Market Status
    • 4.10 Sunovion Pharmaceuticals, Inc.?
      • 4.10.1 Sunovion Pharmaceuticals, Inc.? Profiles
      • 4.10.2 Sunovion Pharmaceuticals, Inc.? Product Information
      • 4.10.3 Sunovion Pharmaceuticals, Inc.? Pulmonary Drugs Business Performance
      • 4.10.4 Sunovion Pharmaceuticals, Inc.? Pulmonary Drugs Business Development and Market Status

    5 Market Performance for Manufacturers

    • 5.1 Europe Pulmonary Drugs Sales (K Units) and Market Share by Manufacturers 2013-2018
    • 5.2 Europe Pulmonary Drugs Revenue (M USD) and Market Share by Manufacturers 2013-2018
    • 5.3 Europe Pulmonary Drugs Price (USD/Unit) of Manufacturers 2013-2018
    • 5.4 Europe Pulmonary Drugs Gross Margin of Manufacturers 2013-2018
    • 5.5 Market Concentration

    6 Regions Market Performance for Manufacturers

    • 6.1 Germany Market Performance for Manufacturers
      • 6.1.1 Germany Pulmonary Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.1.2 Germany Pulmonary Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.1.3 Germany Pulmonary Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.1.4 Germany Pulmonary Drugs Gross Margin of Manufacturers 2013-2018
      • 6.1.5 Market Concentration
    • 6.2 UK Market Performance for Manufacturers
      • 6.2.1 UK Pulmonary Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.2.2 UK Pulmonary Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.2.3 UK Pulmonary Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.2.4 UK Pulmonary Drugs Gross Margin of Manufacturers 2013-2018
      • 6.2.5 Market Concentration
    • 6.3 France Market Performance for Manufacturers
      • 6.3.1 France Pulmonary Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.3.2 France Pulmonary Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.3.3 France Pulmonary Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.3.4 France Pulmonary Drugs Gross Margin of Manufacturers 2013-2018
      • 6.3.5 Market Concentration
    • 6.4 Russia Market Performance for Manufacturers
      • 6.4.1 Russia Pulmonary Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.4.2 Russia Pulmonary Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.4.3 Russia Pulmonary Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.4.4 Russia Pulmonary Drugs Gross Margin of Manufacturers 2013-2018
      • 6.4.5 Market Concentration
    • 6.5 Benelux Market Performance for Manufacturers
      • 6.5.1 Benelux Pulmonary Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.5.2 Benelux Pulmonary Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.5.3 Benelux Pulmonary Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.5.4 Benelux Pulmonary Drugs Gross Margin of Manufacturers 2013-2018
      • 6.5.5 Market Concentration
    • 6.6 Italy Market Performance for Manufacturers
      • 6.6.1 Italy Pulmonary Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.6.2 Italy Pulmonary Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.6.3 Italy Pulmonary Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.6.4 Italy Pulmonary Drugs Gross Margin of Manufacturers 2013-2018
      • 6.6.5 Market Concentration
    • 6.7 Spain Market Performance for Manufacturers
      • 6.7.1 Spain Pulmonary Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.7.2 Spain Pulmonary Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.7.3 Spain Pulmonary Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.7.4 Spain Pulmonary Drugs Gross Margin of Manufacturers 2013-2018
      • 6.7.5 Market Concentration
    • 6.8 Market Performance for Manufacturers
      • 6.8.1 Pulmonary Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.8.2 Pulmonary Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.8.3 Pulmonary Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.8.4 Pulmonary Drugs Gross Margin of Manufacturers 2013-2018
      • 6.8.5 Market Concentration

    7 Europe Pulmonary Drugs Market Performance (Sales Point)

    • 7.1 Europe Pulmonary Drugs Sales (K Units) and Market Share by Regions 2013-2018
    • 7.2 Europe Pulmonary Drugs Revenue (M USD) and Market Share by Regions 2013-2018
    • 7.3 Europe Pulmonary Drugs Price (USD/Unit) by Regions 2013-2018
    • 7.4 Europe Pulmonary Drugs Gross Margin by Regions 2013-2018

    8 Development Trend for Regions (Sales Point)

    • 8.1 Europe Pulmonary Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.2 Germany Pulmonary Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.3 UK Pulmonary Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.4 France Pulmonary Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.5 Russia Pulmonary Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.6 Benelux Pulmonary Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.7 Italy Pulmonary Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.8 Spain Pulmonary Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.8 Spain Pulmonary Drugs Sales and Growth, Sales Value and Growth Rate2013-2018

    9 Upstream Source, Technology and Cost

    • 9.1 Upstream Source
    • 9.2 Technology
    • 9.3 Cost

    10 Channel Analysis

    • 10.1 Market Channel
    • 10.2 Distributors

    11 Consumer Analysis

    • 11.1 Asthma & COPD Industry
    • 11.2 Allergic Rhinitis Industry
    • 11.3 Pulmonary Arterial Hypertension Industry

    12 Market Forecast 2019-2024

    • 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
      • 12.1.1 Europe Pulmonary Drugs Sales (K Units), Revenue (M USD) and Market Share by Regions 2019-2024
      • 12.1.2 Europe Pulmonary Drugs Sales (K Units) and Growth Rate 2019-2024
      • 12.1.3 Germany Pulmonary Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.4 UK Pulmonary Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.5 France Pulmonary Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.6 Russia Pulmonary Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.7 Benelux Pulmonary Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.8 Italy Pulmonary Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.9 Spain Pulmonary Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
    • 12.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
      • 12.3.1 Overall Market Performance
      • 12.3.2 Inhaled Corticosteroids (ICS) Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.3 Long-Acting Beta2-Agonists (LABA) Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.4 Antihistamine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.5 Vasodilators Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
    • 12.4 Sales by Application 2019-2024
      • 12.4.1 Overall Market Performance
      • 12.4.2 Asthma & COPD Sales and and Growth Rate 2019-2024
      • 12.4.3 Allergic Rhinitis Sales and and Growth Rate 2019-2024
      • 12.4.4 Pulmonary Arterial Hypertension Sales and and Growth Rate 2019-2024
      • 12.4.5 Cystic Fibrosis Sales and and Growth Rate 2019-2024
    • 12.5 Price (USD/Unit) and Gross Profit
      • 12.5.1 Europe Pulmonary Drugs Price (USD/Unit) Trend 2019-2024
      • 12.5.2 Europe Pulmonary Drugs Gross Profit Trend 2019-2024

    13 Conclusion

    Geographically, this report split Europe into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Pulmonary Drugs for these regions, from 2012 to 2023 (forecast), including
    Germany
    UK
    France
    Russia
    Benelux
    Italy
    Spain

    Europe Pulmonary Drugs market competition by top manufacturers/players, with Pulmonary Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    AstraZeneca plc
    Bayer AG?
    Teva Pharmaceutical Industries Ltd.?
    Actelion Pharmaceuticals, Inc.
    Boehringer Ingelheim GmbH
    F. Hoffmann-La Roche Ltd.
    Merck & Co., Inc.
    Novartis AG
    GlaxoSmithKline plc
    Sunovion Pharmaceuticals, Inc.?

    On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
    Inhaled Corticosteroids (ICS)
    Long-Acting Beta2-Agonists (LABA)
    Antihistamine
    Vasodilators
    Short-Acting Beta2-Agonists (SABA)
    Anticholinergics
    ? ? Combination Drugs
    ? ? MAbs
    ? ? Enzymes
    ? ? Antibiotics & Antileukotrienes

    On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Pulmonary Drugs for each application, including
    Asthma & COPD
    Allergic Rhinitis
    Pulmonary Arterial Hypertension
    Cystic Fibrosis

    If you have any special requirements, please let us know and we will offer you the report as you want.

    Buy now